The Current Ratio as of September 2024 (TTM) for Alkermes plc (ALKS) is 2.99

According to Alkermes plc’s latest financial reports and current stock price. The company's current Current Ratio is 2.99. This represents a change of -1.03% compared to the average of 3.02 of the last 4 quarters.

Alkermes plc (ALKS) Historical Current Ratio (quarterly & annually)

How has ALKS Current Ratio performed in the past?

The mean historical Current Ratio of Alkermes plc over the last ten years is 3.64. The current 2.99 Current Ratio has changed 8.12% with respect to the historical average. Over the past ten years (40 quarters), ALKS's Current Ratio was at its highest in in the March 2015 quarter at 8.79. The Current Ratio was at its lowest in in the March 2022 quarter at 2.19.

Alkermes plc (ALKS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Alkermes plc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Alkermes plc (ALKS) Average Current Ratio

How has ALKS Current Ratio performed in the past?

The current Current Ratio of Alkermes plc (ALKS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Alkermes plc (ALKS) Current Ratio vs. Peers

How is ALKS’s Current Ratio compared to its peers?

Alkermes plc’s Current Ratio is less than Intra-Cellular Therapies, Inc. (7.81), less than Ironwood Pharmaceuticals, Inc. (3.92), less than Deciphera Pharmaceuticals, Inc. (4.19), less than Pacira BioSciences, Inc. (6.82), less than ANI Pharmaceuticals, Inc. (3.97), greater than Dr. Reddy's Laboratories Limited (2.55), greater than Collegium Pharmaceutical, Inc. (1.11), greater than Eagle Pharmaceuticals, Inc. (2.16), greater than Phibro Animal Health Corporation (2.94), less than Prestige Consumer Healthcare Inc. (3.23), less than Neurocrine Biosciences, Inc. (4.19), less than Dynavax Technologies Corporation (14.18), less than Amphastar Pharmaceuticals, Inc. (3.52), greater than Evolus, Inc. (2.92),

Build a custom stock screener for Alkermes plc (ALKS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alkermes plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Alkermes plc (ALKS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Alkermes plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.